Here are a couple of previous posts on TIL:
From April: TILs (tumor infiltrating lymphocytes) - advancing as melanoma immunotherapy and new trial
From May: TIL - Tumor infiltrating lymphocytes (a bit of a primer)
This was published in March:
Basically, this study looked at doing pretty much the old-fashioned version of TIL: Harvest cells from a tumor, grow cells, give old-time chemo to deplete the patient's existing t cells, infuse t cells that have been grown, then follow with IL-2 as usual...BUT in this case - with a decreasing dose in hopes of retaining the benefit and minimizing the suffering IL-2 can produce. Of 25 patients, there were 3 complete response and 7 partial ones. Median overall survival was almost 22 months. Not surprisingly, tumor regression and clinical responses were related to the greater number of t cells infused and the persistence of the anti-melanoma t cell responses in the patient's blood.
For what it's worth. - c